Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1
Cancer Cell · 2025-01 · 43 (1) · 86-102.e10
DOI: 10.1016/j.ccell.2024.11.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell, 2025-01. Verfasst von Zhen Yang und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Medicinal Chemical Biology, Institute of Immunology, College of Life Sciences, Nankai University, Tianjin 300071, China. Hauptthemen laut MEDLINE: CD28 Antigens, B7-H1 Antigen, Triple Negative Breast Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 84-mal zitiert (Crossref) und nennt 76 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Chinese Academy of Meteorological Sciences.
Abstract (Originalsprache)
Deciphering mechanisms for cancer immune escape may provide targets for improving immunotherapy efficacy. By in vivo genome-wide CRISPR loss-of-function screening in a mouse model of triple negative breast cancer (TNBC), we uncovered a non-classical function of Cd28 in cancer cells to promote immune escape. Knocking out Cd28 in cancer cells increased infiltration of type I conventional DC (cDC1) and activated tumor-specific CD8+ T cells, and pharmaceutical inducible knockdown of Cd28 inhibited pre-established tumor growth and overcame anti-PD-1 resistance in vivo. Furthermore, high expression of cancer cell CD28 in human TNBC tissues correlated with elevated PD-L1 expression, less CD8+ T cell infiltration, and poor prognosis. Mechanistically, intracellular CD28 directly bound to Cd274 mRNA and recruited spliceosomal factor SNRPB2 to stabilize Cd274 mRNA in nucleus, promoting PD-L1 expression and immune escape. Therefore, disrupting cancer cell CD28-mediated immune escape may provide a potential approach to improve breast cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Medicinal Chemical Biology, Institute of Immunology, College of Life Sciences, Nankai University, Tianjin 300071, China.
- Department of Immunology, Center for Immunotherapy, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing 100005, China.
- State Key Laboratory of Medicinal Chemical Biology, Institute of Immunology, College of Life Sciences, Nankai University, Tianjin 300071, China; Department of Immunology, Center for Immunotherapy, Institute of Basic Med…
- National Key Laboratory of Immunity and Inflammation, Department of Pathology, Changhai Hospital, Navy Medical University, Shanghai 200433, China.
- Department of Breast Cancer Pathology, Cancer Institute and Hospital, Tianjin Medical University, Tianjin 300060, China.
Förderung
- National Natural Science Foundation of China
- Chinese Academy of Meteorological Sciences
Zitieren
APA
Yang, Z., Liu, X., Zhu, J., Chai, Y., Cong, B., Li, B., Gao, W., Hu, Y., Wen, M., Liu, Y., Fu, L., & Cao, X. (2025). Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1. Cancer Cell, 43(1), 86-102.e10. https://doi.org/10.1016/j.ccell.2024.11.008
Vancouver
Yang Z, Liu X, Zhu J, Chai Y, Cong B, Li B, et al. Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1. Cancer Cell. 2025;43(1):86-102.e10. doi:10.1016/j.ccell.2024.11.008
BibTeX
@article{Yang2025,
author = {Yang, Zhen and Liu, Xinpeng and Zhu, Jun and Chai, Yangyang and Cong, Boyi and Li, Bo and Gao, Wanfeng and Hu, Ye and Wen, Mingyue and Liu, Yanfang and Fu, Li and Cao, Xuetao},
title = {Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1},
journal = {Cancer Cell},
year = {2025},
volume = {43},
number = {1},
pages = {86--102.e10},
doi = {10.1016/j.ccell.2024.11.008}
}
EUVIMED